by Jordana Choucair | Jan 20, 2022 | Life Sciences
Two Democratic Senators called on the Federal Trade Commission (FTC) to investigate reports of “price gouging and scams” tied to at-home COVID-19 tests. In a letter to FTC Chair Lina Khan, Senators Ed Markey and Richard Blumenthal said that the agency...
by Jordana Choucair | Jan 19, 2022 | Life Sciences
Pfizer Inc. said its COVID-19 antiviral pill, Paxlovid, was effective against the omicron variant in three separate lab tests. The development is an encouraging sign given some other COVID-19 treatments appear not to work as well. Even so, supply of Paxlovid remains...
by Jordana Choucair | Jan 18, 2022 | Life Sciences
A small study of Israeli medical workers found that a fourth dose of the Pfizer-BioNTechCOVID-19 vaccine wasn’t enough to prevent infection with the Omicron variant. However, the extra shot did raise antibody levels. The trial’s lead researcher said the...
by Jordana Choucair | Jan 13, 2022 | Life Sciences
White House COVID-19 Response Coordinator Jeffrey D. Zients said that the federal government is buying another 500,000 doses of AstraZeneca PLC’s antibody drug for COVID-19. The order will bring total U.S. supply to 1.2 million doses, to be shipped by the end of...
by Jordana Choucair | Jan 12, 2022 | Life Sciences
Medicare officials said the program should restrict coverage of Aduhelm, Biogen’s Alzheimer’s drug, to patients participating in randomized, controlled clinical trials. The agency made its decision after reviewing scientific evidence and various stakeholder opinions...
by Jordana Choucair | Jan 12, 2022 | Life Sciences
The federal government ordered another 600,000 doses of GlaxoSmithKline PLC and Vir Biotechnology Inc.’s monoclonal antibody treatment for COVID-19. The drugmakers plan to deliver the treatment, which is the only one thought to work against the Omicron variant,...
Recent Comments